BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 31699828)

  • 1. Genomic Determinants of Clinical Outcomes in Rhabdomyosarcoma.
    Casey DL; Wexler LH; Pitter KL; Samstein RM; Slotkin EK; Wolden SL
    Clin Cancer Res; 2020 Mar; 26(5):1135-1140. PubMed ID: 31699828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrative clinical and biopathology analyses to understand the clinical heterogeneity of infantile rhabdomyosarcoma: A report from the French MMT committee.
    Butel T; Karanian M; Pierron G; Orbach D; Ranchere D; Cozic N; Galmiche L; Coulomb A; Corradini N; Lacour B; Proust S; Guerin F; Boutroux H; Rome A; Mansuy L; Vérité C; Defachelles AS; Tirode F; Minard-Colin V
    Cancer Med; 2020 Apr; 9(8):2698-2709. PubMed ID: 32087612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and mutational spectrum of highly differentiated, paired box 3:forkhead box protein o1 fusion-negative rhabdomyosarcoma: A report from the Children's Oncology Group.
    Teot LA; Schneider M; Thorner AR; Tian J; Chi YY; Ducar M; Lin L; Wlodarski M; Grier HE; Fletcher CDM; van Hummelen P; Skapek SX; Hawkins DS; Wagers AJ; Rodriguez-Galindo C; Hettmer S
    Cancer; 2018 May; 124(9):1973-1981. PubMed ID: 29461635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor mutational burden and driver mutations: Characterizing the genomic landscape of pediatric brain tumors.
    Patel RR; Ramkissoon SH; Ross J; Weintraub L
    Pediatr Blood Cancer; 2020 Jul; 67(7):e28338. PubMed ID: 32386112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group.
    Hibbitts E; Chi YY; Hawkins DS; Barr FG; Bradley JA; Dasgupta R; Meyer WH; Rodeberg DA; Rudzinski ER; Spunt SL; Skapek SX; Wolden SL; Arndt CAS
    Cancer Med; 2019 Oct; 8(14):6437-6448. PubMed ID: 31456361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TP53 mutations increase radioresistance in rhabdomyosarcoma and Ewing sarcoma.
    Casey DL; Pitter KL; Wexler LH; Slotkin EK; Gupta GP; Wolden SL
    Br J Cancer; 2021 Aug; 125(4):576-581. PubMed ID: 34017087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beyond "Triton": Malignant Peripheral Nerve Sheath Tumors With Complete Heterologous Rhabdomyoblastic Differentiation Mimicking Spindle Cell Rhabdomyosarcoma.
    Hornick JL; Nielsen GP
    Am J Surg Pathol; 2019 Oct; 43(10):1323-1330. PubMed ID: 31107719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic profiling of pleomorphic rhabdomyosarcoma reveals a genomic signature distinct from that of embryonal rhabdomyosarcoma.
    Saoud C; Dermawan JK; Sharma AE; Tap W; Wexler LH; Antonescu CR
    Genes Chromosomes Cancer; 2024 May; 63(5):e23238. PubMed ID: 38722224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines.
    Taylor AC; Shu L; Danks MK; Poquette CA; Shetty S; Thayer MJ; Houghton PJ; Harris LC
    Med Pediatr Oncol; 2000 Aug; 35(2):96-103. PubMed ID: 10918230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epithelioid and spindle rhabdomyosarcoma with TFCP2 rearrangement in abdominal wall: a distinctive entity with poor prognosis.
    Li Y; Li D; Wang J; Tang J
    Diagn Pathol; 2023 Mar; 18(1):41. PubMed ID: 36998041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrent secondary genomic alterations in desmoplastic small round cell tumors.
    Chow WA; Yee JK; Tsark W; Wu X; Qin H; Guan M; Ross JS; Ali SM; Millis SZ
    BMC Med Genet; 2020 May; 21(1):101. PubMed ID: 32393201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Copy number alteration is an independent prognostic biomarker in triple-negative breast cancer patients.
    Nagahashi M; Ling Y; Toshikawa C; Hayashida T; Kitagawa Y; Futamura M; Kuwayama T; Nakamura S; Yamauchi H; Yamauchi T; Kaneko K; Kanbayashi C; Sato N; Tsuchida J; Moro K; Nakajima M; Shimada Y; Ichikawa H; Lyle S; Miyoshi Y; Takabe K; Okuda S; Wakai T
    Breast Cancer; 2023 Jul; 30(4):584-595. PubMed ID: 36930419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium.
    Shern JF; Selfe J; Izquierdo E; Patidar R; Chou HC; Song YK; Yohe ME; Sindiri S; Wei J; Wen X; Rudzinski ER; Barkauskas DA; Lo T; Hall D; Linardic CM; Hughes D; Jamal S; Jenney M; Chisholm J; Brown R; Jones K; Hicks B; Angelini P; George S; Chesler L; Hubank M; Kelsey A; Gatz SA; Skapek SX; Hawkins DS; Shipley JM; Khan J
    J Clin Oncol; 2021 Sep; 39(26):2859-2871. PubMed ID: 34166060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children's oncology group report.
    Skapek SX; Anderson J; Barr FG; Bridge JA; Gastier-Foster JM; Parham DM; Rudzinski ER; Triche T; Hawkins DS
    Pediatr Blood Cancer; 2013 Sep; 60(9):1411-7. PubMed ID: 23526739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical and prognostic analysis of single-center multidisciplinary treatment for rhabdomyosarcoma in children].
    Xu N; Duan C; Jin M; Zhang DW; Su Y; Yu T; He LJ; Fu LB; Zeng Q; Wang HM; Zhang WP; Ni X; Ma XL
    Zhonghua Er Ke Za Zhi; 2019 Oct; 57(10):767-773. PubMed ID: 31594063
    [No Abstract]   [Full Text] [Related]  

  • 16. Relationship of DNA methylation to mutational changes and transcriptional organization in fusion-positive and fusion-negative rhabdomyosarcoma.
    Sun W; Chatterjee B; Shern JF; Patidar R; Song Y; Wang Y; Walker RL; Pawel BR; Linardic CM; Houghton P; Hewitt SM; Edelman DC; Khan J; Meltzer PS; Barr FG
    Int J Cancer; 2019 Jun; 144(11):2707-2717. PubMed ID: 30565669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rhabdomyosarcoma associated with germline TP53 alteration in children and adolescents: The French experience.
    Pondrom M; Bougeard G; Karanian M; Bonneau-Lagacherie J; Boulanger C; Boutroux H; Briandet C; Chevreau C; Corradini N; Coze C; Defachelles AS; Galmiche-Roland L; Orbach D; Piguet C; Scoazec JY; Vérité C; Willems M; Frebourg T; Minard V; Brugières L
    Pediatr Blood Cancer; 2020 Sep; 67(9):e28486. PubMed ID: 32658383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification.
    Missiaglia E; Williamson D; Chisholm J; Wirapati P; Pierron G; Petel F; Concordet JP; Thway K; Oberlin O; Pritchard-Jones K; Delattre O; Delorenzi M; Shipley J
    J Clin Oncol; 2012 May; 30(14):1670-7. PubMed ID: 22454413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rhabdomyosarcoma: How Advanced Molecular Methods Are Shaping the Diagnostic and Therapeutic Paradigm.
    Giannikopoulos P; Parham DM
    Pediatr Dev Pathol; 2021; 24(5):395-404. PubMed ID: 34107813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer.
    Ricciuti B; Kravets S; Dahlberg SE; Umeton R; Albayrak A; Subegdjo SJ; Johnson BE; Nishino M; Sholl LM; Awad MM
    J Immunother Cancer; 2019 Mar; 7(1):87. PubMed ID: 30922388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.